New
HealthMore in Health→
Stem Cell Transplants Show Long-Term Benefit in Severe Sclerosis
Key Takeaways
- The NISSC1-LTE study followed 80 patients for a median 9.2 years after autologous HCT.
- Estimated 10-year progression-free and overall survival were 60% and 71%, respectively.
- The findings add long-term evidence for carefully selected patients with early severe systemic sclerosis.
DE
DT Editorial Team··via medicalxpress.com